Display Settings:

Format

Send to:

Choose Destination
Hematol Oncol Clin North Am. 2011 Aug;25(4):813-33. doi: 10.1016/j.hoc.2011.04.006.

Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.

Author information

  • 1Medical Oncology Department, Institut Gustave Roussy, 114 Rue Edouard Vaillant, Villejuif, France.

Abstract

Vascular endothelial growth factor (VEGF) is, to date, the key element in the pathogenesis of renal cell carcinoma (RCC). VEGF pathway activation is responsible for the recruitment, migration, and expansion of endothelial cells, with this angiogenesis tumor model being characteristic of RCC. Different strategies have been developed for almost a decade to block the VEGF pathway in this setting. Four different compounds were approved for metastatic RCC (mRCC) in the past 6 years: bevacizumab, sunitinib, sorafenib, and pazopanib. Axitinib and tivozanib are also promising compounds under evaluation. The revolution in the management and prognosis of patients with mRCC is ongoing.

Copyright © 2011 Elsevier Inc. All rights reserved.

PMID:
21763969
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk